The GUSTO trial: background and baseline characteristics

Area of Science:

• Cardiology
• Thrombosis Research
• Clinical Trials

Background:

• Acute coronary thrombosis is a leading cause of mortality.
• Early reperfusion therapy is critical for improving outcomes.
• Previous studies suggested thrombolytic therapy improves survival.

Purpose of the Study:

• To test if early sustained patency with thrombolytic regimens improves mortality in acute coronary thrombosis.
• To compare the efficacy and safety of four different thrombolytic treatment strategies.
• To evaluate the impact of adjunctive heparin and different thrombolytic agents.

Main Methods:

• A large-scale randomized controlled trial involving 41,021 patients.
• Comparison of four treatment arms: streptokinase (SK) with subcutaneous heparin, SK with intravenous heparin, accelerated tissue plasminogen activator (t-PA) with intravenous heparin, and combined SK and t-PA.
• Patients received treatment within a mean of two hours, with aggressive investigation and revascularization strategies.

Main Results:

• No significant difference in mortality was observed between the four thrombolytic regimens.
• The study provided extensive data on the outcomes of different thrombolytic strategies in a large patient cohort.
• Nearly 3000 patients were enrolled from Australia and New Zealand, contributing to the global understanding of these treatments.

Conclusions:

• Achieving early sustained patency with the tested thrombolytic regimens did not significantly improve mortality in acute coronary thrombosis.
• The GUSTO trial results underscore the complexity of optimizing treatment for acute myocardial infarction.
• Findings should be interpreted considering the aggressive investigation and revascularization strategies employed.